Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Cupressuflavone (CAS No. 3952-18-9) is a natural flavonoid compound derived from the cypress plant Cupressus macrocarpa. As a polyphenolic dimer flavonoid, cypress biflavonoids have attracted widespread attention in the field of natural product pharmacology in recent years due to their unique chemical structure and diverse biological activities. Numerous studies have shown that cypress biflavonoids have significant anti-inflammatory, anti-ulcer, and hepatorenal protective effects, especially showing good protective effects in models of CCl4-induced mouse hepatorenal toxicity. Moreover, increasing evidence supports its potential applications in neuroprotection, involving multiple key molecular targets such as BCL2, APP, BACE1, MAPT, SIRT1, suggesting it may achieve prevention and treatment of neurological diseases through multi-target regulation.

This paper aims to systematically review the chemical structure and physicochemical properties of cypress biflavones, plant origin and extraction process, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and to explore their potential and future development directions in clinical applications, aiming to provide a theoretical foundation and reference for further research and drug development of this natural product.

Chemical structure and physicochemical properties

Cypress diflavones belong to the flavonoid dimer class, with the molecular formula C30H18O10 and a molecular weight of 538.4640. Its structure is formed by connecting two flavonoid units via carbon-carbon bonds, featuring a typical polyphenol hydroxyl group structure that gives it strong antioxidant capacity. Its molecular structure contains multiple phenolic hydroxyl groups and benzene rings, characterized by high polarity and complex spatial conformation.

In terms of physicochemical properties, the LogP value of cypress biflavones is 3.2843, indicating moderate lipid solubility that facilitates cell membrane penetration, but their water solubility is relatively low (0.0030), limiting their solubility and bioavailability in aqueous biological systems. Its topological pole surface area (TPSA) is 181.8 Ų, and a higher TPSA value is usually related to molecular polarity and the number of hydrogen bond donor receptors, suggesting certain limitations when crossing biofilms (such as the blood-brain barrier). The blood-brain barrier permeability was assessed as low, indicating that cypress biflavones have difficulty directly entering the central nervous system, but their neuroprotective effects may be realized through indirect mechanisms or peripheral nervous system intervention. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames trial scored 0.6, indicating a low genotoxicity risk and a solid safety foundation.

Plant Origins and Extraction Methods

Cypress biflavonoids are mainly found in Cupressus macrocarpa (large-leaf cypress), a plant widely distributed along the Mediterranean coast and in North America, traditionally used to prevent and treat various diseases. As an important active ingredient in this plant, cypress biflavonoids are usually obtained through plant extraction and separation purification.

The extraction method mainly uses organic solvent extraction technology, with commonly used solvents including ethanol, methanol, and their aqueous solution systems. The typical process flow typically includes: after drying and crushing plant materials, reflux extraction with 70% ethanol. After concentration, the extract is separated and purified using liquid-liquid partitioning and column chromatography techniques (such as silica gel columns, reversed-phase C18 columns). High-performance liquid chromatography (HPLC) and mass spectrometry (MS) techniques are widely used for qualitative and quantitative analysis of cypress biflavonoids.

In recent years, emerging technologies such as ultrasound-assisted extraction (UAE) and microwave-assisted extraction (MAE) have also been tried for the extraction of cypress biflavonoids to improve yield and extraction efficiency, reduce the amount of organic solvents, and align with the concept of green chemistry.

Pharmacological activity research

Anti-inflammatory effects

Cypress biflavonoids exhibit significant anti-inflammatory activity. Both in vitro and in vivo experiments have confirmed its ability to inhibit the production of various inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and prostaglandin E2 (PGE2). Its anti-inflammatory mechanism may be closely related to the activation of the nuclear factor κB (NF-κB) signaling pathway, thereby reducing the expression of pro-inflammatory genes.

Anti-ulcer activity

In terms of gastrointestinal protection, cypress biflavonoids have shown protective effects against various ulcer models. Its mechanisms include enhancing the gastric mucosa's defense function, inhibiting gastric acid secretion, and reducing oxidative stress damage. Animal experiments have shown that cypress biflavonoids can significantly reduce gastric mucosal damage induced by alcohol and nonsteroidal anti-inflammatory drugs (NSAIDs), promoting ulcer healing.

Liver and kidney protective effects

For CCl4-induced mouse hepatorenal toxicity models, cypress biflavones demonstrated good protective effects. Its mechanism of action involves antioxidant, anti-inflammatory, and apoptosis regulation. Cypress biflavones can significantly reduce serum transaminases (ALT, AST) and renal function indicators (BUN, Cr), alleviate pathological damage to liver and kidney tissues, and enhance endogenous antioxidant enzyme activity and reduce reactive oxygen species (ROS) generation by activating the nuclear factor 2-related factor 2 (NRF2) signaling pathway.

Neuroprotective effects

Research on cypress biflavonoids in the field of neuroprotection is gradually increasing. It works by regulating various neuro-related targets, including anti-apoptotic protein BCL2, amyloid precursor protein (APP), β-secretase BACE1, microtubule-associated protein Tau (MAPT), deacetycholinesterase (ACHE), serine protease CASP3, α-synuclein (SNCA), and longevity protein SIRT1. Relevant studies have shown that cypress biflavones can reduce nerve cell damage, inhibit neuroinflammation, improve cognitive impairment, and have potential value in the prevention and treatment of Alzheimer's and Parkinson's diseases.

Mechanism of action and molecular targets

The multi-target mechanism of cypress biflavones forms the basis of its various pharmacological activities. It mainly involves the following aspects:

1. Regulation of antioxidant and anti-inflammatory pathways
   Cypress biflavonoids promote the expression of downstream antioxidant enzymes (such as superoxide dismutase SOD and glutathione peroxidase GPx) by activating the NRF2 signaling pathway, clearing excess ROS and reducing oxidative stress damage. At the same time, it inhibits the NF-κB signaling pathway, reduces the expression of pro-inflammatory factors, and alleviates inflammatory responses.

2. Regulation of apoptosis
   By upregulating the anti-apoptotic protein BCL2 and inhibiting the activation of the pro-apoptotic protein CASP3, cypress biflavones protect cells from apoptosis induction and maintain tissue structure and function.

3. Regulation of neuroprotection-related targets
   Cypress biflavonoids can regulate Alzheimer's-related proteins APP and BACE1, reduce β-amyloid production, and inhibit neurotoxic deposition. At the same time, it regulates abnormal phosphorylation of tau protein and reduces the formation of nerve fiber tangles. Activation of SIRT1 promotes neuronal survival and metabolic homeostasis, improving cognitive function.

4. Regulation of neurotransmitter metabolism
   By inhibiting acetylcholinesterase (ACHE) activity, cypress biflavonoids increase acetylcholine levels, improve nerve conduction function, and help alleviate cognitive impairment.

5. Protein aggregation-related protein regulation
   Cypress diflavones regulate α-synuclein (SNCA) expression and help reduce neuronal toxic aggregation in Parkinson's disease.

Druggability evaluation and pharmacokinetics

Druggability evaluation is a crucial step in the development of natural product drugs. The physicochemical properties of cypress biflavonoids show moderate lipid solubility (LogP 3.28), which facilitates cell membrane penetration, but their poor water solubility limits their oral bioavailability. A higher TPSA value (181.8) and low blood-brain barrier permeability suggest that it is difficult to directly enter the central nervous system, but this does not rule out its neuroprotective effects through peripheral nervous system or indirect mechanisms.

In terms of toxicological evaluation, the hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. Ames test results showed that it carries low genotoxicity risk and is relatively safe.

Currently, research on pharmacokinetics is relatively limited. Preliminary data indicate that cypress biflavones are slowly absorbed orally and have low plasma concentrations, possibly due to their low water solubility and large molecular weight. Its metabolic pathway may involve the liver phase I and phase II enzyme systems, but the specific metabolites and their activities require further investigation. Future research should focus on improving its pharmacokinetic properties, such as enhancing bioavailability and targeting through nanocarriers, liposomes, or structural modifications.

Prospects and outlooks for clinical applications

With its multi-target and multi-pathway pharmacological activity, Cypress Biflavonoids demonstrate broad clinical application potential. Its anti-inflammatory, anti-ulcer, and liver-kidney protective effects provide new treatment approaches for chronic inflammatory diseases and liver and kidney injury. Especially in the field of neuroprotection, cypress biflavones have the potential to become adjunctive therapies for neurodegenerative diseases by regulating targets related to Alzheimer's and Parkinson's diseases.

However, clinical research on cypress biflavones is still in its early stages and lacks systematic clinical trial data. In the future, its pharmacokinetics, toxicology, and preclinical evaluation should be strengthened, and its dosage forms and administration routes optimized to improve its in vivo stability and targeting. At the same time, combining modern drug design and biotechnological methods, structural modification and derivative development are being carried out to explore broader pharmacological applications.

In addition, as a natural product, the sustainable use and quality control of cypress biflavonoids are also important guarantees for clinical promotion. Standardized extraction processes and quality evaluation systems should be established to ensure stable sources and consistency of ingredients.

Conclusion

As a natural flavonoid dimer with multiple pharmacological activities, Cypress biflavonoids demonstrate therapeutic potential in anti-inflammatory, anti-ulcer, liver-kidney, and neuroprotective properties. Its complex mechanism involves multiple key molecular targets, demonstrating the advantages of natural products in regulating diseases with multiple targets. Although there are certain challenges to druggability, such as poor water solubility and low blood-brain barrier permeability, modern drug development technologies are expected to overcome these limitations.

In the future, in-depth research on cypress biflavones should focus on pharmacokinetic optimization, mechanistic analysis, and clinical translation, promoting their transition from laboratory to clinical application. As an important member in the field of natural product pharmacology, the development of cypress biflavones not only enriches natural drug resources but also provides new strategies and hope for the treatment of various diseases.